These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 15191351)
1. Cyclin E correlates with malignancy and adverse prognosis in adrenocortical tumors. Tissier F; Louvel A; Grabar S; Hagnéré AM; Bertherat J; Vacher-Lavenu MC; Dousset B; Chapuis Y; Bertagna X; Gicquel C Eur J Endocrinol; 2004 Jun; 150(6):809-17. PubMed ID: 15191351 [TBL] [Abstract][Full Text] [Related]
2. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Gicquel C; Bertagna X; Gaston V; Coste J; Louvel A; Baudin E; Bertherat J; Chapuis Y; Duclos JM; Schlumberger M; Plouin PF; Luton JP; Le Bouc Y Cancer Res; 2001 Sep; 61(18):6762-7. PubMed ID: 11559548 [TBL] [Abstract][Full Text] [Related]
3. Molecular markers for malignancy in adrenocortical tumors. Gicquel C; Le Bouc Y Horm Res; 1997; 47(4-6):269-72. PubMed ID: 9167963 [TBL] [Abstract][Full Text] [Related]
4. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. Gicquel C; Bertagna X; Schneid H; Francillard-Leblond M; Luton JP; Girard F; Le Bouc Y J Clin Endocrinol Metab; 1994 Jun; 78(6):1444-53. PubMed ID: 7911125 [TBL] [Abstract][Full Text] [Related]
5. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. Gicquel C; Raffin-Sanson ML; Gaston V; Bertagna X; Plouin PF; Schlumberger M; Louvel A; Luton JP; Le Bouc Y J Clin Endocrinol Metab; 1997 Aug; 82(8):2559-65. PubMed ID: 9253334 [TBL] [Abstract][Full Text] [Related]
6. [Sporadic adrenocortical tumors: genetics and perspectives for the pathologist]. Tissier F Ann Pathol; 2008 Oct; 28(5):409-16. PubMed ID: 19068395 [TBL] [Abstract][Full Text] [Related]
7. High expression of cyclin E and G1 CDK and loss of function of p57KIP2 are involved in proliferation of malignant sporadic adrenocortical tumors. Bourcigaux N; Gaston V; Logié A; Bertagna X; Le Bouc Y; Gicquel C J Clin Endocrinol Metab; 2000 Jan; 85(1):322-30. PubMed ID: 10634406 [TBL] [Abstract][Full Text] [Related]
8. Pediatric adrenocortical tumors: molecular events leading to insulin-like growth factor II gene overexpression. Wilkin F; Gagné N; Paquette J; Oligny LL; Deal C J Clin Endocrinol Metab; 2000 May; 85(5):2048-56. PubMed ID: 10843195 [TBL] [Abstract][Full Text] [Related]
9. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Libè R; Groussin L; Tissier F; Elie C; René-Corail F; Fratticci A; Jullian E; Beck-Peccoz P; Bertagna X; Gicquel C; Bertherat J Clin Cancer Res; 2007 Feb; 13(3):844-50. PubMed ID: 17289876 [TBL] [Abstract][Full Text] [Related]
10. A case report in favor of a multistep adrenocortical tumorigenesis. Bernard MH; Sidhu S; Berger N; Peix JL; Marsh DJ; Robinson BG; Gaston V; Le Bouc Y; Gicquel C J Clin Endocrinol Metab; 2003 Mar; 88(3):998-1001. PubMed ID: 12629075 [TBL] [Abstract][Full Text] [Related]
12. Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. Boulle N; Logié A; Gicquel C; Perin L; Le Bouc Y J Clin Endocrinol Metab; 1998 May; 83(5):1713-20. PubMed ID: 9589681 [TBL] [Abstract][Full Text] [Related]
13. Loss of heterozygosity of 17p13, with possible involvement of ACADVL and ALOX15B, in the pathogenesis of adrenocortical tumors. Soon PS; Libe R; Benn DE; Gill A; Shaw J; Sywak MS; Groussin L; Bertagna X; Gicquel C; Bertherat J; McDonald KL; Sidhu SB; Robinson BG Ann Surg; 2008 Jan; 247(1):157-64. PubMed ID: 18156936 [TBL] [Abstract][Full Text] [Related]
14. [Pathology of adrenocortical tumors: review and recent data]. Tissier F Ann Endocrinol (Paris); 2009 Jun; 70(3):179-85. PubMed ID: 19298951 [TBL] [Abstract][Full Text] [Related]
15. [Involvement of the IGF system in the pathogenesis of adrenocortical tumors]. Gicquel C; Boulle N; Logié A; Bourcigaux N; Gaston V; Le Bouc Y Ann Endocrinol (Paris); 2001 Apr; 62(2):189-92. PubMed ID: 11353893 [TBL] [Abstract][Full Text] [Related]
16. Identification of Clinical and Biologic Correlates Associated With Outcome in Children With Adrenocortical Tumors Without Germline TP53 Mutations: A St Jude Adrenocortical Tumor Registry and Children's Oncology Group Study. Pinto EM; Rodriguez-Galindo C; Pounds SB; Wang L; Clay MR; Neale G; Garfinkle EAR; Lam CG; Levy CF; Pappo AS; Zambetti GP; Ribeiro RC J Clin Oncol; 2017 Dec; 35(35):3956-3963. PubMed ID: 29058986 [TBL] [Abstract][Full Text] [Related]
17. Pediatric adrenocortical neoplasms: immunohistochemical expression of p57 identifies loss of heterozygosity and abnormal imprinting of the 11p15.5. Giovannoni I; Boldrini R; Benedetti MC; Inserra A; De Pasquale MD; Francalanci P Pediatr Res; 2017 Mar; 81(3):468-472. PubMed ID: 27842055 [TBL] [Abstract][Full Text] [Related]
18. Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas. Semczuk A; Marzec B; Skomra D; Roessner A; Cybulski M; Rechberger T; Schneider-Stock R Oncology; 2005; 69(4):317-25. PubMed ID: 16293976 [TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor system on adrenocortical tumorigenesis. Ribeiro TC; Latronico AC Mol Cell Endocrinol; 2012 Mar; 351(1):96-100. PubMed ID: 22019903 [TBL] [Abstract][Full Text] [Related]
20. Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. Almeida MQ; Fragoso MC; Lotfi CF; Santos MG; Nishi MY; Costa MH; Lerario AM; Maciel CC; Mattos GE; Jorge AA; Mendonca BB; Latronico AC J Clin Endocrinol Metab; 2008 Sep; 93(9):3524-31. PubMed ID: 18611974 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]